Results 261 to 270 of about 192,321 (310)

The Scientific Basis of Drug-Drug Interactions: Mechanism and Preclinical Evaluation

Drug Information Journal, 1998
Pharmacokinetic drug-drug interactions (PDDI), in which the pharmacokinetic clearance of one drug is altered by a coadministered drug, can be divided mechanistically into two general categories: 1. Inhibitory PDDI—the inhibition of the metabolic clearance of one drug by a coadministered drug, and 2.
openaire   +1 more source

NCI Specialized Procedures in Preclinical Drug Evaluations

2004
Agents now come to the U.S. National Cancer Institute (NCI) from many sources for preclinical evaluation and/or potential development (1). In most cases, experimental agents have limited antiproliferative data against a broad spectrum of human cancers, and these agents usually are then tested in the NCI’ s in vitro anticancer drug screen. Data from the
Melinda G. Hollingshead, Michael C. Alley, Gurmeet Kaur, Christine M. Pacula-Cox, Sherman F. Stinson   +4 more
openaire   +1 more source

Preclinical Evaluation of Cudetaxestat for Potential Drug-Drug Interactions

B36. SPECTRUM OF FIBROTIC INTERSTITIAL LUNG DISEASES, 2022
W. Yu, R. Rajagopalan, J. Lin, P. Ibrahim   +3 more
openaire   +1 more source

Evaluation of Antiseptic Drug Candidate Pyridosept in Preclinical in Vitro Studies

Current Medicinal Chemistry
Introduction: This work provides preclinical in vitro studies of an innovative antimicrobial agent named pyridosept, belonging to the quaternary bis-ammonium salts and synthesized on the base of pyridoxine. Since the wide spread of pathogens with tolerance to both antibiotics and antiseptics challenges the ...
Renata Kazakova, Alfiya Iksanova, Mariya Agafonova, Anna Lubina, Elena Bulatova, Elena Nikitina, Svetlana Lisovskaya, Airat Kayumov, Oxana Bondar, Albina Malanyeva, Olga Vasileva, Marina Zeldi, Alina Gatina, Sergei Koshkin, Natalia Komcharova, Yulia Konyakhina, Kseniia Titova, Aleksandr Sergeev, Sergey Sapozhnikov, Nikita Shtyrlin, Yurii Shtyrlin   +20 more
openaire   +2 more sources

Preclinical Drug Evaluation with Human Melanoma Xenografts

1988
In 1974 there was an increasing awareness at the National Cancer Institute of the U.S.A. that important drugs might have been missed by the conventional murine tumor screening system then employed. Differences in biochemistry and cell biology of murine vs. human tumors were increasingly well understood.
openaire   +1 more source

Preclinical Evaluation of Neuraxial Drugs for Safety

2023
Tony L. Yaksh, Robert B. Boyd, Orion Paul Keifer   +2 more
openaire   +1 more source

Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs

2005
Type I and II DNA topoisomerases are the targets for numerous clinically efficacious antitumor agents. Over the last decade, considerable effort has been expended in developing camptothecin (CPT) derivatives that selectively target DNA topoisomerase I (TOP-I) (1).
Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, Peter J. Houghton   +3 more
openaire   +1 more source

ChemInform Abstract: Drug Safety Evaluation at the Preclinical Stage

ChemInform, 1991
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
openaire   +1 more source

Preclinical evaluation of drug effects on testicular functions

Pharmacology & Therapeutics, 1979
F, Neumann, B, Schenck
openaire   +2 more sources

PPreclinical Evaluation of Drugs for Evidence of Teratogenic Activity

Journal of Pharmaceutical Sciences, 1963
“If certain congenital malformations can be attributed in certain animals to dietary deficiency, anoxia, cortisone, or genetic constellations, one must not conclude without further proof that comparable malformations in man are due to similar adverse conditions.
openaire   +2 more sources